Aemetis (NASDAQ:AMTX) Lowered to Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Aemetis from hold to sell, adding to mixed analyst sentiment on the stock. The broader consensus remains Hold, with a consensus price target of $8.58.
• Aemetis shares were under pressure, opening at $2.59 and falling 17.0% in the article's headline coverage. The stock is trading well below the consensus target and has a market cap of about $176.5 million.
• The company reported a Q1 earnings miss, posting -$0.33 EPS versus expectations of -$0.27, and revenue of $54.62 million versus an expected $66.70 million. Analysts now expect Aemetis to lose $1.08 per share for the current year.

Aemetis (NASDAQ:AMTX - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

A number of other equities analysts have also weighed in on the company. Ascendiant Capital Markets boosted their target price on Aemetis from $20.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday, April 8th. Loop Capital set a $1.75 target price on shares of Aemetis in a report on Thursday, March 12th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Aemetis in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $8.58.

Aemetis Stock Down 17.0%

NASDAQ:AMTX opened at $2.59 on Friday. The company's 50 day moving average price is $2.49 and its 200-day moving average price is $1.98. Aemetis has a 52 week low of $1.26 and a 52 week high of $3.80. The stock has a market cap of $176.51 million, a price-to-earnings ratio of -2.18 and a beta of 1.46.

Aemetis (NASDAQ:AMTX - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The specialty chemicals company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.06). The firm had revenue of $54.62 million for the quarter, compared to analysts' expectations of $66.70 million. As a group, sell-side analysts anticipate that Aemetis will post -1.08 earnings per share for the current year.

Institutional Investors Weigh In On Aemetis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning bought a new position in Aemetis in the second quarter worth approximately $30,000. Virtu Financial LLC bought a new position in Aemetis in the fourth quarter worth approximately $31,000. Sanctuary Advisors LLC bought a new position in Aemetis in the first quarter worth approximately $33,000. HRT Financial LP bought a new position in Aemetis in the fourth quarter worth approximately $36,000. Finally, Centiva Capital LP bought a new position in Aemetis in the third quarter worth approximately $39,000. Hedge funds and other institutional investors own 27.02% of the company's stock.

About Aemetis

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.